The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. Trial Registration: Clinical Research Information Service Identifier: KCT0004672
Abstract
BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. Trial Registration: Clinical Research Information Service Identifier: KCT0004672
참고문헌 (25)
- Mayans L, "Metabolic syndrome : insulin resistance and prediabetes", FP Essent, 435, pp.11~16 (2015)
- 허지혜, "Impact of Longitudinal Changes in Metabolic Syndrome Status over 2 Years on 10-Year Incident Diabetes Mellitus", Diabetes and Metabolism Journal, 43(4), pp.530~538 (2019), 대한당뇨병학회[DOI]
- Graf BL, "Plant-derived therapeutics for the treatment of metabolic syndrome", Curr Opin Investig Drugs, 11, pp.1107~1115 (2010)
- Marles RJ, "Antidiabetic plants and their active constituents", Phytomedicine, 2, pp.137~189 (1995)
- Sultana S, "Review : Medicinal plants combating against hypertension : a green antihypertensive approach", Pak J Pharm Sci, 30, pp.2311~2319 (2017)
- Cabral CE, "Phytosterols in the treatment of hypercholesterolemia and prevention of cardiovascular diseases", Arq Bras Cardiol, 109, pp.475~482 (2017)
- Park BY, "Isolation and anticomplement activity of compounds from Dendropanax morbifera", J Ethnopharmacol, 90, pp.403~408 (2004)
- Bae K, "The Medicinal Plants of Korea" (2000), Kyo-Hak Publishing
- Hyun TK, "Anti-inflammatory activity and phenolic composition of Dendropanax morbifera leaf extracts", Ind Crops Prod, 74, pp.263~270 (2015)
- Moon HI, "Antidiabetic effects of dendropanoxide from leaves of Dendropanax morbifera Leveille in normal and streptozotocin-induced diabetic rats", Hum Exp Toxicol, 30, pp.870~875 (2011)
- Kang MJ, "Polyacetylene from Dendropanax morbifera alleviates diet-induced obesity and hepatic steatosis by activating AMPK signaling pathway", Front Pharmacol, 9, pp.537~ (2018)
- Chung IM, "Antiatherogenic activity of Dendropanax morbifera essential oil in rats", Pharmazie, 64, pp.547~549 (2009)
- 조용복, "황칠나무 추출물이 고혈압에 미치는 영향에 관한 연구", 한국산학기술학회논문지, 17(11), pp.708~715 (2016), 한국산학기술학회[DOI]
- Yang HY, "Dendropanax morbifera ameliorates thioacetamide-induced hepatic fibrosis via TGF-β1", Smads pathways, 2019, pp.15, 800~811
- Birhanu BT, "An in vivo immunomodulatory and anti-inflammatory study of fermented Dendropanax morbifera Léveille leaf extract", BMC Complement Altern Med, 18, pp.222~ (2018)
- Akram M, "Potent anti-inflammatory and analgesic actions of the chloroform extract of Dendropanax morbifera mediated by the Nrf2", HO-1 pathway, 2016, pp.39, 728~736
- American Diabetes Association, "2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2019", Diabetes Care, 42, pp.S13~28 (2019)
- 안나영, "Streptozotocin에 의해 유도된 당뇨모델동물에서 황칠나무 (Dendropanax morbifera Leveille)의 열수추출물과 에탄올추출물의 당뇨 질환 개선 효능", Journal of Nutrition and Health, 47(6), pp.394~402 (2014), 한국영양학회
- 담효동, "황칠나무 잎 추출물이 고지방·고콜레스테롤 식이를 급여한 마우스의 지질 개선 효과에 미치는 영향", 한국식품영양과학회지, 44(5), pp.641~648 (2015), 한국식품영양과학회
- 송지혜, "Antiobesity and Cholesterol-Lowering Effects of Dendropanax morbifera Water Extracts in Mouse 3T3-L1 Cells", Journal of Medicinal Food, 21(8), pp.793~800 (2018), 한국식품영양과학회[DOI]
- 윤지선, "황칠나무 추출물의 고지혈증 완화 효과 스크리닝", Journal of Applied Biological Chemistry, 61(1), pp.1~8 (2018), 한국응용생명화학회
- Soleimani M, "Insulin resistance and hypertension : new insights", Kidney Int, 87, pp.497~499 (2015)
- Saad MF, "Insulin resistance and hypertension : the Insulin Resistance Atherosclerosis study", Hypertension, 43, pp.1324~1331 (2004)
- Esposito K, "The metabolic syndrome and inflammation : association or causation?", Nutr Metab Cardiovasc Dis, 14, pp.228~232 (2004)
- Choo GS, "Anti-inflammatory effects of Dendropanax morbifera in lipopolysaccharide-stimulated RAW264.7 macrophages and in an animal model of atopic dermatitis", Mol Med Rep, 19, pp.2087~2096 (2019)